Education
About Us
Working with TipRanks
Follow Us
Reviva Pharmaceuticals Holdings (RVPH)
NASDAQ:RVPH
RESEARCH TOOLSreports
Total Valuation
Reviva Pharmaceuticals Holdings has a market cap or net worth of $39.00M. The enterprise value is ―.
Market Cap$39.00M
Enterprise Value―
Share Statistics
Reviva Pharmaceuticals Holdings has 46,739,950 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding46,739,950
Owned by Insiders4.49%
Owned by Institutions5.02%
Financial Efficiency
Reviva Pharmaceuticals Holdings’s return on equity (ROE) is -6.87M and return on invested capital (ROIC) is 260853806542.37%.
Return on Equity (ROE)-6.87M
Return on Assets (ROA)-1.66M
Return on Invested Capital (ROIC)260853806542.37%
Return on Capital Employed (ROCE)-6.05M
Revenue Per Employee0.00
Profits Per Employee-2.80M
Employee Count14
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Reviva Pharmaceuticals Holdings is >-0.01. Reviva Pharmaceuticals Holdings’s PEG ratio is -0.05.
PE Ratio>-0.01
PS Ratio0.00
PB Ratio-3.23
Price to Fair Value21.43
Price to FCF-1.33
Price to Operating Cash Flow-0.97
PEG Ratio-0.05
Income Statement
In the last 12 months, Reviva Pharmaceuticals Holdings had revenue of 0.00 and earned -39.26T in profits. Earnings per share was -1.65.
Revenue0.00
Gross Profit0.00
Operating Income-39.50T
Pretax Income-39.24M
Net Income-39.26T
EBITDA-39.50T
Earnings Per Share (EPS)-1.65
Cash Flow
In the last 12 months, operating cash flow was -33.32M and capital expenditures 0.00, giving a free cash flow of -33.32M billion.
Operating Cash Flow-33.32M
Free Cash Flow-33.32M
Free Cash Flow per Share-0.71
Dividends & Yields
Reviva Pharmaceuticals Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.91
52-Week Price Change-50.88%
50-Day Moving Average0.87
200-Day Moving Average1.28
Relative Strength Index (RSI)50.19
Average Volume (3m)751.68K
Important Dates
Reviva Pharmaceuticals Holdings upcoming earnings date is May 19, 2025, TBA Not Confirmed.
Last Earnings DateMar 31, 2025
Next Earnings DateMay 19, 2025
Ex-Dividend Date―
Financial Position
Reviva Pharmaceuticals Holdings as a current ratio of 1.38, with Debt / Equity ratio of -0.83%
Current Ratio1.38
Quick Ratio1.38
Debt to Market Cap0.00
Net Debt to EBITDA<0.01
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Reviva Pharmaceuticals Holdings has paid -16.95B in taxes.
Income Tax-16.95B
Effective Tax Rate431.89
Enterprise Valuation
Reviva Pharmaceuticals Holdings EV to EBITDA ratio is >-0.01, with an EV/FCF ratio of -3.50.
EV to Sales0.00
EV to EBITDA>-0.01
EV to Free Cash Flow-3.50
EV to Operating Cash Flow-3.50
Balance Sheet
Reviva Pharmaceuticals Holdings has $5.56M in cash and marketable securities with $83.00K in debt, giving a net cash position of -$5.48M billion.
Cash & Marketable Securities$5.56M
Total Debt$83.00K
Net Cash-$5.48M
Net Cash Per Share-$0.12
Tangible Book Value Per Share$0.24
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Reviva Pharmaceuticals Holdings is $11.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$11.25
Price Target Upside1239.29% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast45.15%